Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
波士顿,2024年5月8日(GLOBE NEWSWIRE)——Aura Biosciences, Inc.(纳斯达克股票代码:AURA)是一家临床阶段的生物技术公司,该公司正在开发精准免疫疗法,旨在保持癌症器官的功能。该公司今天宣布,首席执行官伊丽莎白·德洛斯·皮诺斯博士将参加以下即将举行的投资者会议:
-
The Citizens JMP Life Sciences Conference on Monday, May 13, 2024.
Fireside Chat at 9:00 a.m. ET.
- 公民JMP生命科学会议将于2024年5月13日星期一举行。
美国东部时间上午 9:00 的炉边谈话
-
TD Cowen 5th Annual Oncology Innovation Summit on Wednesday, May 29, 2024.
Fireside Chat at 10:00 a.m. ET.
- TD Cowen第五届年度肿瘤学创新峰会将于2024年5月29日星期三举行。
美国东部时间上午 10:00 的炉边谈话。
The live webcasts of both fireside chats will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company's website at , where a replay of the webcast will be archived for 90 days following the presentation date.
两次炉边谈话的网络直播将在公司网站 “活动与演讲” 部分下的 “投资者与媒体” 页面上播出 ,网络直播的重播将在演讲之日起的90天内存档。
About Aura Biosciences
关于奥拉生物科学
Aura Biosciences is a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer. Our lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. We are evaluating the safety and efficacy of bel-sar as a potential vision-sparing therapy in an ongoing global Phase 3 CoMpass trial for the first-line treatment of adult patients with early-stage choroidal melanoma. Bel-sar is also being evaluated in additional solid cancers, including bladder cancer. Our mission is to develop vision and organ-sparing therapies to improve patient outcomes in cancer. Aura is headquartered in Boston, MA. For more information, visit aurabiosciences.com. Visit us @AuraBiosciences and on LinkedIn.
Aura Biosciences是一家处于临床阶段的生物技术公司,开发用于治疗实体瘤的精准免疫疗法,旨在保持癌症器官的功能。我们的主要候选药物bel-sar处于治疗原发性脉络膜黑色素瘤和其他眼部肿瘤适应症患者的后期临床开发阶段,膀胱癌的早期临床开发也处于早期阶段。我们正在进行的一项针对早期脉络膜黑色素瘤成年患者一线治疗的全球3期ComPass试验中,我们正在评估bel-sar作为潜在的视力保护疗法的安全性和有效性。Bel-SAR还正在接受其他实体癌(包括膀胱癌)的评估。我们的使命是开发视力和器官保护疗法,以改善癌症患者的预后。Aura 总部位于马萨诸塞州波士顿。欲了解更多信息,请访问 aurabiosciences.com。拜访我们 @AuraBiosciences 然后继续 领英。
Investors and Media:
投资者和媒体:
Alex Dasalla
Head of Investor Relations and Corporate Communications
adasalla@aurabiosciences.com
亚历克斯·达萨拉
投资者关系和企业传播主管
adasalla@aurabiosciences.com
Source: Aura Biosciences, Inc.
资料来源:Aura Biosciences, Inc.